Showing 4951-4960 of 5234 results for "".
FDA Warns on Expression; Lilly's Ixekizumab Data Promising
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-warns-on-expression-lilly-s-ixekizumab-data-promising/19093/Lilly's Ixekizumab phase III data look good for psoriasis, and the FDA warns on improper use of Expression hyaluronic acid as a dermal filler. Plus, Sitavig is available for herpes labialis, and Syneron's laser gets an onychomycosis clearance.ASLMS 2024 Meeting Wrap-Up
https://practicaldermatology.com/topics/news/aslms-2024-meeting-wrapup/24462/The American Society for Laser Medicine and Surgery (ASLMS) recently wrapped its 43rd Annual Conference on Energy-based Medicine and Science in Baltimore (ASLMS 2024), where leading practitioners and researchers gathered to share groundbreaking advancements and insights in the field of laser medicinUnlocking the Potential of Regenerative Medicine in Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/unlocking-the-potential-of-regenerative-medicine-in-dermatology/24022/Advances in regenerative medicine have led to a new generation of therapeutic approaches and options.Advancing Digital Medicine in Dermatology
https://practicaldermatology.com/series/the-practical-dermatology-podcast/advancing-digital-medicine-in-dermatology/18187/The Digital Medicine Society (DiME) is a global nonprofit dedicated to advancing the ethical, effective, equitable, and safe use of digital medicine to redefine health care and improve lives. DiME recently released a new set of resources, available at www.dimesociety.org/access-resources/, to advancHow Exceptional Reception Design Can Maximize Sales
https://practicaldermatology.com/topics/practice-management/how-exceptional-reception-design-can-maximize-sales/23779/Many factors determine the impact of this generally small but important space.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/programs/practical-dermatology/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pDermWireTV: Skyrizi for PsA; Toxins and Wound Healing at Maui Derm; SDDS Registration
https://practicaldermatology.com/topics/psoriasis/skyrizi-for-psa-toxins-and-wound-healing-at-maui-derm-sdds-registration-dermwiretv/20057/Skyrizi (AbbVie) is now approved for the treatment of adults with active psoriatic arthritis. Michael Gold, MD was among the speakers who offered updates on cosmetic trends as well as medical care at Maui Dermatology for Dermatologists last week. He spoke about high-dose neurotoxins. Robert KirsnerDisability Income Insurance: What Every Young Dermatologist Needs to Know
https://practicaldermatology.com/topics/practice-management/disability-income-insurance-what-every-young-dermatologist-needs-to-know/23597/Getting disability income insurance at an early age may offer lower rates and long-term peace of mind.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.Inclusivity: A Concerted Effort
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/inclusivity-a-concerted-effort/19915/Historical events and recent developments contribute to some patients’ skepticism of medicine in general and dermatology specifically. Hear what panelists say about the best approaches to expand inclusivity in research, clinical trials, and patient care. It will take a concerted effort to overcome c